{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T05:25:48Z","timestamp":1793683548610,"version":"4.5.1"},"reference-count":38,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1707,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1111\/j.1600-0609.2010.01552.x","type":"journal-article","created":{"date-parts":[[2010,11,11]],"date-time":"2010-11-11T19:45:44Z","timestamp":1289504744000},"page":"117-123","source":"Crossref","is-referenced-by-count":6,"title":["Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma"],"prefix":"10.1111","volume":"86","author":[{"given":"Hirokazu","family":"Nagai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michinori","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Kusumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoko","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiko","family":"Motoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Ohyashiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Ohnishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Omachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomitsu","family":"Hotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,12,29]]},"reference":[{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood.V62.4.737.737","article-title":"Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes","volume":"62","author":"Carson","year":"1983","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"9567","DOI":"10.1073\/pnas.95.16.9567","article-title":"Induction of an apoptotic program in cell-free extracts by 2-chloro-2\u2032-deoxyadenosine 5\u2032-triphosphate and cytochrome c","volume":"95","author":"Leoni","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1002\/cncr.21447","article-title":"Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5\u2003years","volume":"104","author":"Else","year":"2005","journal-title":"Cancer"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1080\/10428190600822052","article-title":"2-CdA in the treatment of hairy cell leukemia: a review of long-term follow-up","volume":"47","author":"Gidron","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.1998.16.9.3007","article-title":"Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients","volume":"16","author":"Cheson","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1056\/NEJM199403103301007","article-title":"Newer purine analogues for the treatment of hairy-cell leukemia","volume":"330","author":"Saven","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1111\/j.1349-7006.2009.01162.x","article-title":"Phase I\/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab","volume":"100","author":"Tobinai","year":"2009","journal-title":"Cancer Sci"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1023\/A:1008325110921","article-title":"Fludarabine and cladribine in relapsed\/refractory low-grade non-Hodgkin\u2019s lymphoma: a phase II randomized study","volume":"11","author":"Tondini","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1532\/IJH97.04050","article-title":"Treatment of indolent non-Hodgkin\u2019s lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone","volume":"79","author":"Armitage","year":"2004","journal-title":"Int J Hematol"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1200\/JCO.1994.12.4.788","article-title":"2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin\u2019s lymphoma","volume":"12","author":"Hoffman","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1200\/JCO.2009.23.6315","article-title":"Rituximab and subcutaneous 2-chloro-2\u2032-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study","volume":"28","author":"Laszlo","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/annonc\/mdl126","article-title":"Prolonged clinical remission in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with cladribine: 6\u2003year follow-up of a phase II trial","volume":"17","author":"Jager","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/cncr.23558","article-title":"Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group","volume":"113","author":"Kalinka-Warzocha","year":"2008","journal-title":"Cancer"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1532\/IJH97.04077","article-title":"Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin\u2019s lymphomas: results of a Japanese phase II study","volume":"80","author":"Ogura","year":"2004","journal-title":"Int J Hematol"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1080\/10428190701361216","article-title":"Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin\u2019s lymphoma","volume":"48","author":"Robak","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1080\/1042819032000159825","article-title":"Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies","volume":"45","author":"Robak","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1200\/JCO.1998.16.3.850","article-title":"Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin\u2019s lymphoma","volume":"16","author":"Betticher","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/S0959-8049(02)00143-0","article-title":"Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin\u2019s lymphoma","volume":"38","author":"Rummel","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1200\/JCO.1996.14.7.2139","article-title":"Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin\u2019s lymphoma","volume":"14","author":"Saven","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1200\/JCO.2009.25.9630","article-title":"Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study)","volume":"28","author":"Robak","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1200\/JCO.2005.02.172","article-title":"Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma","volume":"23","author":"Czuczman","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2004.07.170","article-title":"Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma","volume":"22","author":"Zinzani","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","article-title":"The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1111\/j.1349-7006.2009.01247.x","article-title":"Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma","volume":"100","author":"Tobinai","year":"2009","journal-title":"Cancer Sci"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB29|cit29","volume-title":"World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues","year":"2001"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1200\/JCO.2005.03.9313","article-title":"Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin\u2019s lymphoma","volume":"24","author":"Tobinai","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB36|cit36","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.630.630","article-title":"Cladribine (CdA) gives longer response duration than fludarabine (F) and high-dose intermittent clorambucil (Chl) as first-line treatment of symptomatic chronic lymphocytic leukemia (CLL): first results from the International Randomized Phase III Trial","volume":"110","author":"Karlsson","year":"2007","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB37|cit37","first-page":"385","article-title":"Cellular pharmacokinetics of 2-chloro-2\u2032-deoxyadenosine nucleotides: comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients","volume":"4","author":"Liliemark","year":"1995","journal-title":"Clin Cancer Res"},{"key":"10.1111\/j.1600-0609.2010.01552.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1080\/10428199909169620","article-title":"Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4\u2003+\u2003lymphocytopenia after treatment","volume":"35","author":"Bastie","year":"1999","journal-title":"Leuk Lymphoma"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2010.01552.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1600-0609.2010.01552.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T05:28:51Z","timestamp":1625635731000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2010.01552.x"}},"subtitle":["R-2-CdA therapy for relapsed or refractory indolent B-NHL"],"short-title":[],"issued":{"date-parts":[[2010,12,29]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2010.01552.x","relation":{},"ISSN":["0902-4441"],"issn-type":[{"value":"0902-4441","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12,29]]}}}